You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Internet-based Fidelity Enhancement of MTFC
SBC: Tfc Consultants, Inc. Topic: NIMHDESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies
SBC: 7 Hills Pharma LLC Topic: NIAIDLeukocyte adhesion deficiency type ILADis a rare and often fatal primary immunodeficiencyIt is caused by autosomal recessive mutations in the gene ITGBwhich encodes CDthe commonsubunitof thefamily of integrin cell adhesion molecules that are specifically expressed on cells of hematopoietic origin like leukocytesAs a result of decreased function ofintegrinsleukocytes cannot extravasate from the vas ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract Infections
SBC: Combinati Incorporated Topic: NIAIDAbstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Innovative Computer Prototype for HIV Screening and Brief Intervention
SBC: RESEARCH CIRCLE ASSOCIATES Topic: NIDADESCRIPTION (provided by applicant): HIV continues to be a major public health problem in the United States, but there has been limited penetration of HIV prevention services in many healthcare settings. Novel methods for seamlessly integrating HIV prevention into medical practice are needed. The proposed Phase 1 STTR project seeks to establish the feasibility of designing key components of an inn ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Inhibition of Biofilms on Tympanostomy Tubes
SBC: SELENIUM LTD Topic: NIDCDDESCRIPTION (provided by applicant): Bacterial biofilm formation on medical implants is a serious clinical problem. Biofilms can turn a simple implant into a serious complication. Recently we showed that the covalent attachment of micrograms of organo-selenium to the surface of an orthodontic device will inhibit the formation of a biofilm without harmful side-effects. This has recently (2009) led ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDProject Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Improve Wound Healing with HIF-CA5 DNA Vector and Electroporation
SBC: CANTON BIOTECHNOLOGIES, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Therapy to Improve Wound Healing with DNA Expression Vector for HIF 11 and Electroporation Impaired wound healing is a tremendous problem for individuals with diabetes. Patients with diabetes are at risk for developing foot ulcers. These non-healing ulcerations on the foot are disabling, and their progression leads to amputation of the lower extremity. Diabetes ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Immunotherapeutics to prevent HCV reinfection
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Identification of novel therapeutics for tuberculosis combining cheminformatics,
SBC: COLLABORATIVE DRUG DISCOVERY, INC. Topic: NIAIDDESCRIPTION (provided by applicant): This Small Business Technology Transfer Phase I project entitled Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic-based pathway analysis describes the development of software that will facilitate new drug discovery efforts for Mycobacterium tuberculosis (TB). The amount of research performed on TB co ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Identification and Validation of Targets of Phenotypic High Throughput Screening
SBC: COLLABORATIVE DRUG DISCOVERY, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Identification and Validation of Targets of Phenotypic High Throughput Screening Hits for Chagas Disease Project Summary Nearly 10 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the causative agent of Chagas disease. The World Health Organization (WHO) classifies Chagas disease as a neglected tropical disease, but C ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health